NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis $2.16 +0.06 (+2.86%) Closing price 04:00 PM EasternExtended Trading$2.15 -0.01 (-0.42%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oramed Pharmaceuticals Stock (NASDAQ:ORMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oramed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.12▼$2.1950-Day Range$2.10▼$2.3852-Week Range$1.82▼$3.09Volume47,183 shsAverage Volume142,151 shsMarket Capitalization$88.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Read More Oramed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreORMP MarketRank™: Oramed Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat, and ranked 903rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oramed Pharmaceuticals.Read more about Oramed Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oramed Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.35% of the float of Oramed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 2.88%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.35% of the float of Oramed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 2.88%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.39 News SentimentOramed Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORMP Stock News HeadlinesORMP - Oramed Pharmaceuticals Inc Trailing Returns - Morningstar1 hour ago | morningstar.comMOramed Pharmaceuticals Inc. (ORMP) - Yahoo FinanceJuly 2 at 6:50 PM | ca.finance.yahoo.comBanks aren’t ready for this altcoin—are you?In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?July 2 at 2:00 AM | Crypto 101 Media (Ad)ORMP - Oramed Pharmaceuticals Inc Executives - MorningstarJune 27, 2025 | morningstar.comMWe're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn RateJune 27, 2025 | finance.yahoo.comOramed Pharm Extends Stock Buyback ProgramMay 21, 2025 | tipranks.comThe past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableMay 17, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | finanznachrichten.deSee More Headlines ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed this year? Oramed Pharmaceuticals' stock was trading at $2.42 at the beginning of 2025. Since then, ORMP shares have decreased by 10.7% and is now trading at $2.16. View the best growth stocks for 2025 here. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.16. The biotechnology company had revenue of $2 million for the quarter. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Company Calendar Last Earnings5/15/2025Today7/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORMP CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.06 million Net MarginsN/A Pretax Margin-1,225.60% Return on Equity-11.34% Return on Assets-10.73% Debt Debt-to-Equity RatioN/A Current Ratio23.94 Quick Ratio23.94 Sales & Book Value Annual Sales$1.34 million Price / Sales66.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.61 per share Price / Book0.60Miscellaneous Outstanding Shares40,850,000Free Float35,254,000Market Cap$88.44 million OptionableOptionable Beta1.59 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ORMP) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.